PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 998
- Registration Number
- NCT02718417
- Locations
- 🇺🇸
Investigational Drug Service, Emory University Clinic, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸University Hospital, The Cancer Center, Newark, New Jersey, United States
Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT02711462
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
- Conditions
- Osteoarthritis, HipOsteoarthritis, Knee
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 849
- Registration Number
- NCT02709486
- Locations
- 🇫🇷
CHR Orleans La Source, Orleans, France
🇩🇪Rheumazentrum Prof. Dr. med Gunther Neeck, Bad Doberan, Germany
🇪🇸Hospital La Esperanza, A Coruña, Spain
Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55
- Registration Number
- NCT02708355
- Locations
- 🇺🇸
Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States
🇺🇸St. Anthony Hospital - Conference Rooms, Oklahoma City, Oklahoma, United States
A Study Comparing Amounts of Tafamidis In The Blood Without Food
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02697864
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
- Conditions
- Osteoarthritis, KneeOsteoarthritis, Hip
- Interventions
- Other: PlaceboBiological: Tanezumab 2.5 mgBiological: Tanezumab 2.5mg/5mg
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 698
- Registration Number
- NCT02697773
- Locations
- 🇺🇸
Robert L Freed, M.D., F.A.C.R / Clinical Interventions Research Institute, Irvine, California, United States
🇨🇦Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Biological: PF-05230907
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT02687191
- Locations
- 🇺🇸
Barnes Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 108
- Registration Number
- NCT02687542
- Locations
- 🇺🇸
Hoag Memorial Hospital, Newport Beach, California, United States
🇨🇦Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
Bioavailability Study Of PF-06651600 In Healthy Subjects
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT02684760
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
- Conditions
- Renal Cell Cancer
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 886
- Registration Number
- NCT02684006
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Tower Hematology Oncology Medical Group, Beverly Hills, California, United States